Mycobacterial glycoconjugates as vaccine candidates against tuberculosis

Trends in Microbiology

Volumn 16, Issue 10, 2008, Pages 456-462

  Källenius, Gunilla ^a,b   Pawlowski, Andrzej ^a   Hamasur, Beston ^a   Svenson, Stefan B ^a,c  

^a SWEDISH INSTITUTE FOR INFECTIOUS DISEASE CONTROL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c SWEDISH UNIVERSITY OF AGRICULTURAL SCIENCES   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ARABINOMANNAN; ARABINOMANNAN TETANUS TOXOID CONJUGATE VACCINE; BACTERIAL ANTIGEN; BACTERIAL POLYSACCHARIDE; BACTERIAL PROTEIN; BCG VACCINE; CARBOHYDRATE ANTIGEN; CD1 ANTIGEN; EUROCINE; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; IMMUNOLOGICAL ADJUVANT; LIPOARABINOMANNAN; MYCOBACTERIAL GLYCOCONJUGATE; O ANTIGEN; TETANUS TOXOID; UNCLASSIFIED DRUG; VIRULENCE FACTOR;

ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIGEN PRESENTATION; ARTICLE; BACTERIAL MEMBRANE; CELL SURFACE; CELLULAR IMMUNITY; CLINICAL TRIAL; DRUG EFFICACY; EXPERIMENTAL INFECTION; GUINEA PIG; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; LUNG TUBERCULOSIS; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN CARBOHYDRATE INTERACTION; SURVIVAL TIME; TUBERCULOSIS;

ANIMALS; HUMANS; LIPOPOLYSACCHARIDES; MICE; MYCOBACTERIUM; TUBERCULOSIS VACCINES; TUBERCULOSIS, PULMONARY; VACCINES, CONJUGATE;

CAVIA; MUS; MYCOBACTERIUM TUBERCULOSIS;

EID: 53049090810     PISSN: 0966842X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tim.2008.07.007     Document Type: Article

References (78)

1. Colditz G.A., et al. The efficacy of bacillus Calmette-Guerin vaccination of newborns and infants in the prevention of tuberculosis: meta-analyses of the published literature. Pediatrics 96 (1995) 29-35
2. Skeiky Y.A., and Sadoff J.C. Advances in tuberculosis vaccine strategies. Nat. Rev. Microbiol. 4 (2006) 469-476
3. Lockhart S.P., et al. Pneumococcal conjugate vaccines: emerging clinical information and its implications. Expert Rev. Vaccines 5 (2006) 553-564
4. Kelly D.F., et al. Haemophilus influenzae type b conjugate vaccines. Immunology 113 (2004) 163-174
5. Trotter C.L., and Ramsay M.E. Vaccination against meningococcal disease in Europe: review and recommendations for the use of conjugate vaccines. FEMS Microbiol. Rev. 31 (2007) 101-107
6. Roberts I.S. The biochemistry and genetics of capsular polysaccharide production in bacteria. Annu. Rev. Microbiol. 50 (1996) 285-315
7. + T cells. J. Immunol. 174 (2005) 1787-1790
8. Pecanha L.M., et al. Dextran-conjugated anti-Ig antibodies as a model for T cell-independent type 2 antigen-mediated stimulation of Ig secretion in vitro. I. Lymphokine dependence. J. Immunol. 146 (1991) 833-839
9. Jeurissen A., et al. T lymphocyte dependence of the antibody response to 'T lymphocyte independent type 2' antigens. Immunology 111 (2004) 1-7
10. Wu Z.Q., et al. In vivo polysaccharide-specific IgG isotype responses to intact Streptococcus pneumoniae are T cell dependent and require CD40- and B7-ligand interactions. J. Immunol. 163 (1999) 659-667
11. + T cell help. J. Immunol. 172 (2004) 532-539
12. Fairhurst R.M., et al. CD1 presents antigens from a gram-negative bacterium, Haemophilus influenzae type B. Infect. Immun. 66 (1998) 3523-3526
13. Avery O.T., and Goebel W.F. Chemo-immunological studies on conjugated carbohydrate-proteins. II. Immunological specificity of synthetic sugar-protein antigens. J. Exp. Med. 50 (1929) 533-550
14. Goldblatt D. Conjugate vaccines. Clin. Exp. Immunol. 119 (2000) 1-3
15. Svenson S.B., and Lindberg A.A. Oligosaccharide-protein conjugate: a novel approach for making Salmonella O-antigen immunogens. FEMS Microbiol. Lett. 1 (1977) 145-148
16. Svenson S.B., and Lindberg A.A. Artificial Salmonella vaccines. Prog. Allergy 33 (1983) 120-143
17. Svenson S.B., et al. Artificial Salmonella vaccines: O-antigenic oligosaccharide-protein conjugates induce protection against infection with Salmonella typhimurium. Infect. Immun. 25 (1979) 863-872
18. Lin F.Y., et al. The efficacy of a Salmonella typhi Vi conjugate vaccine in two-to-five-year-old children. N. Engl. J. Med. 344 (2001) 1263-1269
19. Levine M.M., et al. Clinical trials of Shigella vaccines: two steps forward and one step back on a long, hard road. Nat. Rev. Microbiol. 5 (2007) 540-553
20. Paoletti L.C., et al. Effects of chain length on the immunogenicity in rabbits of group B Streptococcus type III oligosaccharide-tetanus toxoid conjugates. J. Clin. Invest. 89 (1992) 203-209
21. Borch R.F., et al. The cyanoborohydride anion as a selective reducing agent. J. Am. Chem. Soc. 93 (1971) 2897-2904
22. Pawlowski A., et al. A new method of non-cross-linking conjugation of polysaccharides to proteins via thioether bonds for the preparation of saccharide-protein conjugate vaccines. Vaccine 17 (1999) 1474-1483
23. Brennan P.J. Structure, function, and biogenesis of the cell wall of Mycobacterium tuberculosis. Tuberculosis (Edinb.) 83 (2003) 91-97
24. Hamasur B., et al. A new rapid and simple method for large-scale purification of mycobacterial lipoarabinomannan. FEMS Immunol. Med. Microbiol. 24 (1999) 11-17
25. Daffe M., and Reyrat J.-M. The Mycobacterial Cell Envelope (2008), ASM Press
26. Cole S.T., et al. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 393 (1998) 537-544
27. Karakousis P.C., et al. Mycobacterium tuberculosis cell envelope lipids and the host immune response. Cell. Microbiol. 6 (2004) 105-116
28. Briken V., et al. Mycobacterial lipoarabinomannan and related lipoglycans: from biogenesis to modulation of the immune response. Mol. Microbiol. 53 (2004) 391-403
29. Daffe M., and Etienne G. The capsule of Mycobacterium tuberculosis and its implications for pathogenicity. Tuber. Lung Dis. 79 (1999) 153-169
30. Hunter S.W., et al. Structure and antigenicity of the phosphorylated lipopolysaccharide antigens from the leprosy and tubercle bacilli. J. Biol. Chem. 261 (1986) 12345-12351
31. Kaplan G., et al. Mycobacterium leprae antigen-induced suppression of T cell proliferation in vitro. J. Immunol. 138 (1987) 3028-3034
32. Moreno C., et al. The inhibitory effects of mycobacterial lipoarabinomannan and polysaccharides upon polyclonal and monoclonal human T cell proliferation. Clin. Exp. Immunol. 74 (1988) 206-210
33. Molloy A., et al. Suppression of T-cell proliferation by Mycobacterium leprae and its products: the role of lipopolysaccharide. Proc. Natl. Acad. Sci. U. S. A. 87 (1990) 973-977
34. Chan J., et al. Lipoarabinomannan, a possible virulence factor involved in persistence of Mycobacterium tuberculosis within macrophages. Infect. Immun. 59 (1991) 1755-1761
35. Sibley L.D., et al. Mycobacterial lipoarabinomannan inhibits gamma interferon-mediated activation of macrophages. Infect. Immun. 56 (1988) 1232-1236
36. Barnes P.F., et al. Cytokine production induced by Mycobacterium tuberculosis lipoarabinomannan. Relationship to chemical structure. J. Immunol. 149 (1992) 541-547
37. Chatterjee D., et al. Structural basis of capacity of lipoarabinomannan to induce secretion of tumor necrosis factor. Infect. Immun. 60 (1992) 1249-1253
38. Hetland G., et al. Involvement of antilipoarabinomannan antibodies in classical complement activation in tuberculosis. Clin. Diagn. Lab. Immunol. 5 (1998) 211-218
39. Wallis R.S., et al. Induction of interleukin 1 and tumor necrosis factor by mycobacterial proteins: the monocyte western blot. Proc. Natl. Acad. Sci. U. S. A. 87 (1990) 3348-3352
40. Hamasur B., et al. Synthesis and immunologic characterisation of Mycobacterium tuberculosis lipoarabinomannan specific oligosaccharide-protein conjugates. Vaccine 17 (1999) 2853-2861
41. Hamasur B., et al. Mycobacterium tuberculosis arabinomannan-protein conjugates protect against tuberculosis. Vaccine 21 (2003) 4081-4093
42. Glatman-Freedman A., et al. Antigenic evidence of prevalence and diversity of Mycobacterium tuberculosis arabinomannan. J. Clin. Microbiol. 42 (2004) 3225-3231
43. Haile M., et al. Nasal boost with adjuvanted heat-killed BCG or arabinomannan-protein conjugate improves primary BCG-induced protection in C57BL/6 mice. Tuberculosis (Edinb.) 85 (2005) 107-114
44. Bosio C.M., et al. Infection of B cell-deficient mice with CDC 1551, a clinical isolate of Mycobacterium tuberculosis: delay in dissemination and development of lung pathology. J. Immunol. 164 (2000) 6417-6425
45. Glatman-Freedman A., and Casadevall A. Serum therapy for tuberculosis revisited: reappraisal of the role of antibody-mediated immunity against Mycobacterium tuberculosis. Clin. Microbiol. Rev. 11 (1998) 514-532
46. Kallenius G., et al. Should a new tuberculosis vaccine be administered intranasally?. Tuberculosis (Edinb.) 87 (2007) 257-266
47. Teitelbaum R., et al. A mAb recognizing a surface antigen of Mycobacterium tuberculosis enhances host survival. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 15688-15693
48. Hamasur B., et al. A mycobacterial lipoarabinomannan specific monoclonal antibody and its F(ab′) fragment prolong survival of mice infected with Mycobacterium tuberculosis. Clin. Exp. Immunol. 138 (2004) 30-38
49. Robertsson J.A., et al. Salmonella typhimurium infection in calves: delayed specific skin reactions directed against the O-antigenic polysaccharide chain. Infect. Immun. 37 (1982) 737-748
50. Pier G.B., and Markham R.B. Induction in mice of cell-mediated immunity to Pseudomonas aeruginosa by high molecular weight polysaccharide and vinblastine. J. Immunol. 128 (1982) 2121-2125
51. Powderly W.G., et al. T lymphocyte-mediated protection against Pseudomonas aeruginosa infection in granulocytopenic mice. J. Clin. Invest. 78 (1986) 375-380
52. Jackson S., et al. A rabbit helper T cell clone reactive against group-specific streptococcal carbohydrate. J. Immunol. 133 (1984) 1553-1557
53. Robertsson J.A., et al. Delayed hypersensitivity skin test for detection of immune responses against Salmonella in cattle. Res. Vet. Sci. 32 (1982) 225-230
54. + αβ T cell pool. J. Immunol. 162 (1999) 366-371
55. + T cells in the CD1-restricted repertoire: derivation of mycobacteria-reactive T cells from leprosy lesions. J. Immunol. 164 (2000) 4790-4796
56. Sieling P.A., et al. CD1-restricted T cell recognition of microbial lipoglycan antigens. Science 269 (1995) 227-230
57. + T cells. Nature 372 (1994) 691-694
58. Roura-Mir C., et al. Mycobacterium tuberculosis regulates CD1 antigen presentation pathways through TLR-2. J. Immunol. 175 (2005) 1758-1766
59. 1d-restricted T cells. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 10685-10690
60. Hansen D.S., and Schofield L. Regulation of immunity and pathogenesis in infectious diseases by CD1d-restricted NKT cells. Int. J. Parasitol. 34 (2004) 15-25
61. Yu K.O., et al. Modulation of CD1d-restricted NKT cell responses by using N-acyl variants of α-galactosylceramides. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 3383-3388
62. Chang Y.J., et al. Potent immune-modulating and anticancer effects of NKT cell stimulatory glycolipids. Proc. Natl. Acad. Sci. U. S. A. 104 (2007) 10299-10304
63. Schmieg J., et al. Superior protection against malaria and melanoma metastases by a C-glycoside analogue of the natural killer T cell ligand α-Galactosylceramide. J. Exp. Med. 198 (2003) 1631-1641
64. 197 conjugate vaccines in a murine model. Vaccine 19 (2000) 1159-1166
65. 4+ T cell cytokine response that correlates with the isotype of antipolysaccharide antibody. J. Infect. Dis. 184 (2001) 931-935
66. Jakobsen H., et al. Early life T cell responses to pneumococcal conjugates increase with age and determine the polysaccharide-specific antibody response and protective efficacy. Eur. J. Immunol. 36 (2006) 287-295
67. Zuercher A.W., et al. Cellular immunity in healthy volunteers treated with an octavalent conjugate Pseudomonas aeruginosa vaccine. Clin. Exp. Immunol. 142 (2005) 381-387
68. Casadevall A., and Pirofski L.A. A reappraisal of humoral immunity based on mechanisms of antibody-mediated protection against intracellular pathogens. Adv. Immunol. 91 (2006) 1-44
69. Lefeber D.J., et al. Th1-directing adjuvants increase the immunogenicity of oligosaccharide-protein conjugate vaccines related to Streptococcus pneumoniae type 3. Infect. Immun. 71 (2003) 6915-6920
70. Haile M., et al. Immunization with heat-killed Mycobacterium bovis bacille Calmette-Guerin (BCG) in Eurocine L3 adjuvant protects against tuberculosis. Vaccine 22 (2004) 1498-1508
71. Mehta P.K., and Khuller G.K. Protective immunity to experimental tuberculosis by mannophosphoinositides of mycobacteria. Med. Microbiol. Immunol. (Berl.) 177 (1988) 265-284
72. Singh A.P., and Khuller G.K. Induction of immunity against experimental tuberculosis with mycobacterial mannophosphoinositides encapsulated in liposomes containing lipid A. FEMS Immunol. Med. Microbiol. 8 (1994) 119-126
73. Rodriguez A., et al. Role of IgA in the defense against respiratory infections IgA deficient mice exhibited increased susceptibility to intranasal infection with Mycobacterium bovis BCG. Vaccine 23 (2005) 2565-2572
74. Werz D.B., and Seeberger P.H. Total synthesis of antigen bacillus anthracis tetrasaccharide - creation of an anthrax vaccine candidate. Angew. Chem. Int. Ed. Engl. 44 (2005) 6315-6318
75. Phalipon A., et al. Characterization of functional oligosaccharide mimics of the Shigella flexneri serotype 2a O-antigen: implications for the development of a chemically defined glycoconjugate vaccine. J. Immunol. 176 (2006) 1686-1694
76. Verez-Bencomo V., et al. A synthetic conjugate polysaccharide vaccine against Haemophilus influenzae type b. Science 305 (2004) 522-525
77. Seeberger P.H., and Werz D.B. Synthesis and medical applications of oligosaccharides. Nature 446 (2007) 1046-1051
78. Navoa J.A., et al. Specificity and diversity of antibodies to Mycobacterium tuberculosis arabinomannan. Clin. Diagn. Lab. Immunol. 10 (2003) 88-94